Heparin-induced thrombocytopenia historical perspective: Difference between revisions
Gerald Chi- (talk | contribs) (Created page with "__NOTOC__ {{Heparin-induced thrombocytopenia}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] ==Overview== ==Histor...") |
mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Heparin-induced thrombocytopenia}} | {{Heparin-induced thrombocytopenia}} | ||
{{CMG}}; | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
| Line 12: | Line 12: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Revision as of 19:24, 17 June 2016
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia historical perspective On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia historical perspective |
|
FDA on Heparin-induced thrombocytopenia historical perspective |
|
CDC on Heparin-induced thrombocytopenia historical perspective |
|
Heparin-induced thrombocytopenia historical perspective in the news |
|
Blogs on Heparin-induced thrombocytopenia historical perspective |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: